Abstract | BACKGROUND: RESULTS: After a median follow-up of 31 months, the 3-year estimated disease free survival(DFS) rate of DCIS-Mi patients was significantly lower than that of pure DCIS patients (89.5% vs 97.1%, P=0.009). Patients with DCIS-Mi or DCIS-T1a tumors had comparable 3-year estimated DFS rates (89.5% vs 94.3%, P=0.13). No significant difference in overall survival (OS) was found among different groups (99.6%, 100% and 99.1% for DCIS, DCIS-Mi and DCIS-T1a, P=0.797). In chemotherapy and trastuzumab-naive DCIS-Mi patients, human epidermal growth factor receptor2 (HER2) positivity (HR=21.8, 95%CI, 1.7-286.8, P=0.019) were independent predictor of worse DFS on multivariate analysis. METHODS: During September 2002 and December 2014, 602 breast cancer patients who underwent radical surgery were retrospectively reviewed. Three hundred and fifty-nine patients (59.6%) had pure DCIS, 84(14.0%) and 159(26.4%) were diagnosed as DCIS-Mi and DCIS-T1a. Clinico-pathological features were compared between different subgroups. CONCLUSIONS:
DCIS-Mi displayed a comparable survival to that of DCIS-T1a and a more aggressive biological nature than pure DCIS. Patients with HER2-positive DCIS-Mi had a worse survival and adjuvant chemotherapy plus target therapy needs to be further optimized in those patients.
|
Authors | Yan Fang, Jiayi Wu, Wei Wang, Xiaochun Fei, Yu Zong, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu |
Journal | Oncotarget
(Oncotarget)
Vol. 7
Issue 39
Pg. 64182-64190
(Sep 27 2016)
ISSN: 1949-2553 [Electronic] United States |
PMID | 27577080
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(analysis)
- Breast Neoplasms
(chemistry, mortality, pathology, therapy)
- Carcinoma, Intraductal, Noninfiltrating
(chemistry, mortality, pathology, therapy)
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Disease Progression
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Mastectomy
- Middle Aged
- Multivariate Analysis
- Neoplasm Invasiveness
- Neoplasm Staging
- Proportional Hazards Models
- Receptor, ErbB-2
(analysis)
- Retrospective Studies
- Risk Factors
- Time Factors
- Treatment Outcome
|